$TAK News

Jury Hits Takeda With $885 Million Antitrust Verdict

Takeda's Rich Pipeline Optionality Is Worth A 'Buy'

Takeda Pharmaceutical Q4 Earnings Call Highlights

Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.

Takeda Pharmaceutical Co Sees FY2026 Adj EPS $3.01; Sees Sales $29.585B

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate

Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Pullback

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?

British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Takeda Announces That The TAK-881-300 Phase 2/3 Clinical Trial In Patients With Primary Immunodeficiency Disease 1 Met Its Primary Endpoint,

Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights

Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?